Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents

Status (n = 395)

n (%) or median (IQR)

Age (years)

60 (52–67)

Sex, M/F (% male)

179/216 (45.3)

Hemoglobin (g/dL)

13.9 (12.9–14.9)

Total bilirubin (mg/dL)

0.9 (0.6–1.2)

AST (U/L)

54 (36–89)

ALT (U/L)

65 (40–103)

Platelet count (× 109/L)

142 (97–190)

HCV genotype, n (%)

 1

326 (82.5)

 2

55 (13.9)

 3

1 (0.3)

 4

1 (0.3)

 6

12 (3.0)

SVR, n (%)

388 (98.2)

Liver cirrhosis, n (%)

133 (33.7)

HCV RNA (log10 IU/mL)

6.62 (6.08–7.09)

APRI

1.19 (0.62–2.45)

FIB-4

2.93 (1.57–5.80)

LSM using ARFI (m/s)

1.73 (1.24–2.25) (n = 252)

  1. ALT alanine aminotransferase, APRI AST/platelet ratio index, AST aspartate aminotransferase, HCV hepatitis C virus, IQR interquartile range, LSM using ARFI liver stiffness measurement using acoustic radiation force impulse elastography, SVR sustained virologic response
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us